Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …

Abstract Programmed death-ligand 1 (PD-L1) on cancer cells engages with programmed
cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple …

Over the past few decades, RNA sequencing has significantly progressed, becoming a
paramount approach for transcriptome profiling. The revolution from bulk RNA sequencing …

The emergence of immune checkpoint inhibitors (ICIs), mainly including anti-programmed
cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) and anti-cytotoxic T …

Programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) is a
negative modulatory signaling pathway for activation of T cell. It is acknowledged that PD …

Immunotherapy utilizing chimeric antigen receptor T cell (CAR-T) therapy holds promise for
hematologic malignancies, however, response rates and associated immune-related …

Background Immune checkpoint inhibitors (ICIs) are promising agents for unresectable
hepatocellular carcinoma (uHCC), but lack effective biomarker to predict outcomes. The gut …

Immune checkpoint inhibitors (ICIs) target advanced malignancies with high efficacy but also
predispose patients to immune-related adverse events like immune-mediated colitis (IMC) …

Abstract Indoleamine 2, 3-dioxygenases (IDO1 and IDO2) and tryptophan 2, 3-dioxygenase
(TDO) are tryptophan catabolic enzymes that catalyze the conversion of tryptophan into …

Chimeric antigen receptor T (CAR-T) cell therapy is an emerging and effective cancer
immunotherapy. Especially in hematological malignancies, CAR-T cells have achieved …